Sponsor Check › Person
Related person on Form D filings · address states as listed: MA, NY, CA · listed Apr 10, 2009 → Feb 28, 2022
Data last updated: Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: not yet · SEC enforcement last checked: not yet
Privacy: business-related public information only. Residential addresses are never shown; only the state from the filing.
The five facts investors ask about first. Each section states what was searched and when. Items still in human review are not shown.
Not yet searched.
Sources to be searched: CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not yet searched. PACER: not searched (RECAP only). · Search queued. Results are added automatically; check back later or follow this page to be notified.
State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — not yet searched; State securities regulators searched: AZ (Corporation Commission Securities Division), CA (DFPI — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), DE (DOJ Investor Protection Unit), TX (State Securities Board), WA (DFI) — last crawled Oct 23, 2026, 9:57 PM ET. Other states: not yet searched.
Not yet searched.
Search queued. Results are added automatically; check back later or follow this page to be notified.
Not yet searched.
Sources to be searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not yet searched. PACER: not searched (RECAP only). · Search queued. Results are added automatically; check back later or follow this page to be notified.
State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
Comparisons are made for sponsors and sponsor groups, not individual people.
0 of 36 offerings report sales commissions; 0 report finder's fees; 0 report proceeds to related persons.
| Source | Offering (latest filing) | Sales commissions | Finder's fees | To insiders | Paid to sell it |
|---|---|---|---|---|---|
| EDGAR ↗ | Sep 11, 2025 D File 021-557260 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 10, 2023 D File 021-489397 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 22, 2022 D File 021-468421 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 22, 2022 D File 021-438335 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 9, 2022 D/A File 021-389517 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 9, 2022 D File 021-436586 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Feb 28, 2022 D File 021-435285 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 22, 2021 D File 021-426368 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 10, 2021 D File 021-420659 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 2, 2021 D File 021-419494 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 4, 2021 D File 021-415544 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 25, 2021 D File 021-411281 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Feb 4, 2021 D/A File 021-371190 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Feb 3, 2021 D/A File 021-370079 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 17, 2020 D File 021-380841 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 29, 2020 D/A File 021-364146 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 29, 2020 D/A File 021-364148 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 1, 2020 D File 021-364151 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 18, 2019 D/A File 021-334782 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 15, 2019 D File 021-351035 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 11, 2019 D File 021-344057 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 2, 2018 D File 021-324958 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 18, 2017 D/A File 021-276663 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jan 6, 2017 D File 021-277814 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Sep 29, 2016 D File 021-271499 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 22, 2015 D/A File 021-228382 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 22, 2015 D File 021-242208 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 29, 2014 D File 021-227346 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 24, 2014 D File 021-227085 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 19, 2013 D File 021-206573 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 15, 2013 D File 021-196513 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Sep 20, 2011 D File 021-166079 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 5, 2009 D File 021-107336 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 21, 2009 D File 021-70770 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 12, 2009 D File 021-111808 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 6, 2009 D File 021-104904 | $0 | $0 | $0 | None listed on this filing |
As reported by the issuer on Form D (Items 12–15), latest filing per offering (one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.
Counted across every filing this person is listed on (latest filing per offering, per issuer).
| Source | Issuer | Role | Filed | Form | Offering | Sold | Investors | Min. investment |
|---|---|---|---|---|---|---|---|---|
| EDGAR ↗ | Galvanize Therapeutics, Inc. group: Galvanize Therapeutics | Director | Sep 11, 2025 | D | $141,066,486 similar: $2,000,000–$19,999,994 | $96,130,465 | 28 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Aulos Bioscience, Inc. | Director | Aug 10, 2023 | D | $20,000,000 similar: $2,000,000–$19,999,994 | $5,000,000 | 1 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Aethon Therapeutics, Inc. | Director | Dec 22, 2022 | D | $30,000,000 similar: $2,000,000–$19,999,994 | $6,000,000 | 2 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Galvanize Therapeutics, Inc. group: Galvanize Therapeutics | Director | Mar 22, 2022 | D | $4,000,000 similar: $2,000,000–$19,999,994 | $4,000,000 | 1 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Galvanize Therapeutics, Inc. group: Galvanize Therapeutics | Director | Mar 9, 2022 | D | $2,000,000 similar: $2,000,000–$19,999,994 | $2,000,000 | 1 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Replicate Bioscience, Inc. | Director | Mar 9, 2022 | D/A | $53,000,000 similar: $2,000,000–$19,999,994 | $20,000,000 | 1 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Marlinspike Therapeutics, Inc. | Director | Feb 28, 2022 | D | $65,000,000 similar: $2,000,000–$19,999,994 | $3,500,000 | 1 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Deep Apple Therapeutics, Inc. | Director | Dec 22, 2021 | D | $52,000,000 similar: $2,000,000–$19,999,994 | $5,000,000 | 1 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Galaxy Medical, Inc. group: Galvanize Therapeutics | Director | Nov 10, 2021 | D | $750,000 similar: $2,000,000–$19,999,994 | $750,000 | 1 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Red Queen Therapeutics, Inc. | Director | Nov 2, 2021 | D | $55,000,000 similar: $2,000,000–$19,999,994 | $5,000,000 | 1 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Galaxy Medical, Inc. group: Galvanize Therapeutics | Director | Oct 4, 2021 | D | $1,250,000 similar: $2,000,000–$19,999,994 | $1,250,000 | 1 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Evercrisp Biosciences, Inc. | Director | Aug 25, 2021 | D | $75,000,000 similar: $2,000,000–$19,999,994 | $3,500,000 | 1 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Replicate Bioscience, Inc. | Director | Feb 16, 2021 | D | $40,000,000 similar: $2,000,000–$19,999,994 | $6,000,000 | 1 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Initial Therapeutics, Inc. | Director | Feb 4, 2021 | D/A | $75,000,000 similar: $2,000,000–$19,999,994 | $3,800,000 | 1 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Nine Square Therapeutics Corp | Director | Feb 3, 2021 | D/A | $50,000,000 similar: $2,000,000–$19,999,994 | $4,200,000 | 1 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Apertor Pharmaceuticals, Inc. | Director | Nov 17, 2020 | D | $50,000,000 similar: $1,694,259–$16,000,000 | $3,000,000 | 1 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Galaxy Medical, Inc. group: Galvanize Therapeutics | Director | Oct 29, 2020 | D/A | $18,000,000 similar: $2,000,000–$19,999,994 | $8,000,000 | 1 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Galvanize Therapeutics, Inc. group: Galvanize Therapeutics | Director | Oct 29, 2020 | D/A | $16,100,863 similar: $2,000,000–$19,999,994 | $6,100,863 | 1 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Initial Therapeutics, Inc. | Director | Jul 16, 2020 | D | $75,000,000 similar: $2,000,000–$19,999,994 | $1,000,000 | 1 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Nine Square Therapeutics Corp | Director | Jul 1, 2020 | D | $50,000,000 similar: $2,000,000–$19,999,994 | $1,000,000 | 1 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Galavant Therapeutics, Inc. | Director | Apr 1, 2020 | D | $100,000 similar: $2,000,000–$19,999,994 | $100,000 | 1 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Galvanize Therapeutics, Inc. group: Galvanize Therapeutics | Director | Apr 1, 2020 | D | $2,000,000 similar: $2,000,000–$19,999,994 | $200,000 | 1 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Galaxy Medical, Inc. group: Galvanize Therapeutics | Director | Apr 1, 2020 | D | $5,000,000 similar: $2,000,000–$19,999,994 | $200,000 | 1 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Galvanize Therapeutics, Inc. group: Galvanize Therapeutics | Director | Nov 18, 2019 | D/A | $43,000,000 similar: $2,000,000–$19,999,994 | $42,514,946 | 1 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Tusker Medical, Inc. | Director | Oct 15, 2019 | D | $5,000,000 similar: $2,000,000–$19,999,994 | $2,000,000 | 1 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Tusker Medical, Inc. | Director | Jul 11, 2019 | D | $4,000,000 similar: $2,000,000–$19,999,994 | $4,000,000 | 1 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Stoke Therapeutics, Inc. | Director | Nov 2, 2018 | D | $90,000,000 similar: $2,000,000–$19,999,994 | $90,000,000 | 14 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Cure Forward Corp. | Director | May 18, 2017 | D/A | $4,499,997 similar: $1,100,015–$10,001,163 | $4,499,997 | 1 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | AILERON THERAPEUTICS INC | Director | Jan 6, 2017 | D | $40,000,000 similar: $2,000,000–$19,999,994 | $30,112,894 | 11 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Cure Forward Corp. | Director | Dec 20, 2016 | D | $3,999,997 similar: $1,100,015–$10,001,163 | $3,999,997 | 1 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Cure Forward Corp. | Director | Sep 29, 2016 | D | $6,125,056 similar: $1,100,015–$10,001,163 | $4,325,056 | 1 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Cure Forward Corp. | Director | Jun 22, 2015 | D | $15,000,000 similar: $1,100,015–$10,001,163 | $3,500,000 | 1 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Cure Forward Corp. | Director | Jun 22, 2015 | D/A | $4,000,000 similar: $1,100,015–$10,001,163 | $4,000,000 | 1 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Cure Forward Corp. | Director | Nov 14, 2014 | D | $2,000,000 similar: $1,100,015–$10,001,163 | $500,000 | 1 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | AILERON THERAPEUTICS INC | Director | Oct 29, 2014 | D | $32,999,999 similar: $2,000,000–$19,999,994 | $19,799,999 | 13 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Syntimmune, Inc. | Director | Oct 24, 2014 | D | $26,000,002 similar: $2,000,000–$19,999,994 | $8,000,001 | 5 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | AILERON THERAPEUTICS INC | Director | Nov 19, 2013 | D | $30,000,000 similar: $2,000,000–$19,999,994 | $15,000,003 | 11 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Eledon Pharmaceuticals, Inc. | Director | May 15, 2013 | D | $35,499,985 similar: $2,000,000–$19,999,994 | $19,999,993 | 19 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Eledon Pharmaceuticals, Inc. | Executive Officer, Director | Sep 20, 2011 | D | $22,999,986 similar: $2,000,000–$19,999,994 | $1,892,794 | 6 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | HeartWare International, Inc. | Director | Oct 5, 2009 | D | $220,000 similar: $829,831–$9,999,998 | $220,000 | 1 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Gloucester Pharmaceuticals Inc | Director | Aug 21, 2009 | D | $28,881,642 similar: $2,000,000–$19,999,994 | $20,324,914 | 9 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | HeartWare International, Inc. | Director | Aug 14, 2009 | D | $55,000,000 similar: $829,831–$9,999,998 | $55,000,000 | 30 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Gloucester Pharmaceuticals Inc | Director | Aug 12, 2009 | D | $500,000 similar: $2,000,000–$19,999,994 | $500,000 | 8 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Gloucester Pharmaceuticals Inc | Director | Jul 17, 2009 | D | $500,000 similar: $2,000,000–$19,999,994 | $500,000 | 8 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | AILERON THERAPEUTICS INC | Director | Jun 12, 2009 | D | $40,150,000 similar: $2,000,000–$19,999,994 | $28,105,002 | 8 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Gloucester Pharmaceuticals Inc | Director | Jun 10, 2009 | D | $1,500,000 similar: $2,000,000–$19,999,994 | $1,500,000 | 8 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Eledon Pharmaceuticals, Inc. | Executive Officer, Director | May 6, 2009 | D | $22,000,000 similar: $2,000,000–$19,999,994 | $10,000,000 | 10 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Gloucester Pharmaceuticals Inc | Director | May 6, 2009 | D | $1,700,000 similar: $2,000,000–$19,999,994 | $1,700,000 | 8 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Gloucester Pharmaceuticals Inc | Director | Apr 10, 2009 | D | $1,500,000 similar: $2,000,000–$19,999,994 | $1,500,000 | 8 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
Every row is a Form D or D/A on which the issuer listed this name as a related person. Related-person names are matched on first + last name and the address state on the filing; records that share a name but could not be tied together by a second identifier are listed separately below.
"Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); Pharmaceuticals / 506(b) (800 filings); Other Technology / 506(b) (17,390 filings); Other Health Care / 506(b) (4,189 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Not linked to this profile — a second identifier (same issuer, same sponsor group) was not found. Could be the same person or a different one.
People and management entities the issuers listed as related persons on the same Form D filings as Seth Harrison. Source: the EDGAR rows in the table above. Showing the 40 with the most shared filings.
None found in sources searched.
Sources searched: SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 · Last checked Oct 23, 2026, 8:41 PM ET.
Export this report as PDF (members · included free during the launch period)
No corrections have been requested for this page.
Free. Logged with status: received → under review → fixed / confirmed with source.
If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.
Members get an email when Seth Harrison appears on a new Form D, or when a court case or SEC action is matched to them. See plans →